Answers are grounded in this paper and cite their sources.
Observational study demonstrates cardioprotective effects of engeletin in doxorubicin-induced cardiotoxicity, highlighting NF-κB and Cyt-c/CASP-3 pathways.
Purpose: The goal of this study was to assess the effects of Engeletin (ENG) on apoptosis via the Cytochrome c/ Caspase 3 (Cyt-c/CASP-3) pathway, fibrosis via the Transforming Growth Factor Beta 1 (TGF-β1) pathway, and oxidative status via the Nuclear Factor kappa-light-chain-enhancer of activated B cells/ Inducible Nitric Oxide Synthase (NF-κB/iNOS) signaling cascade, in doxorubicin (DOX)-induced cardiotoxicity. Materials and Methods: The study sample included five groups: Control, DOX (1 µM), DOX + ENG 10 µM, DOX + ENG 20 µM, and DOX + ENG 40 µM. Gene expression levels in the proinflammatory, apoptotic, and fibrotic signal cascades were quantified by real-time reverse transcription-quantitative polymerase chain reaction analysis. Oxidative stress parameters were determined by spectrophotometric analysis. Results: Data demonstrate that ENG substantially improved H9c2 cell viability, diminished lactate dehydrogenase (LDH) levels (52%), and attenuated DOX-induced ROS generation. Furthermore, ENG down-regulated proinflammatory cytokines and inflammatory enzymes through NF-κB inactivation. The data also showed that ENG inhibited cardiomyocyte apoptosis by downregulating Cyt-c, CASP-3, and B-cell lymphoma 2/ Bcl-2-associated X protein (Bcl2/BAX) expression in the apoptotic pathway. Conclusion: These observations suggest the cardioprotective effect of ENG on DOX-induced cardiotoxicity by attenuating oxidative stress, cardiomyofibrosis, and apoptosis.
No takes yet. Share an insight, caveat, or question.
Çınar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: